Pancreatitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Pancreatitis - Pipeline Review, H1 2016', provides an overview of the Pancreatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pancreatitis - The report reviews pipeline therapeutics for Pancreatitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pancreatitis therapeutics and enlists all their major and minor projects - The report assesses Pancreatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pancreatitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pancreatitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Pancreatitis Overview 7 Therapeutics Development 8 Pipeline Products for Pancreatitis - Overview 8 Pipeline Products for Pancreatitis - Comparative Analysis 9 Pancreatitis - Therapeutics under Development by Companies 10 Pancreatitis - Therapeutics under Investigation by Universities/Institutes 11 Pancreatitis - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Pancreatitis - Products under Development by Companies 15 Pancreatitis - Products under Investigation by Universities/Institutes 16 Pancreatitis - Companies Involved in Therapeutics Development 17 Angion Biomedica Corp. 17 Atox Bio Inc. 18 Bharat Serums And Vaccines Limited 19 CalciMedica, Inc. 20 Dynavax Technologies Corporation 21 Generon (Shanghai) Corporation Ltd. 22 GlaxoSmithKline Plc 23 Pharming Group N.V. 24 Pancreatitis - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 AB-103 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 AEM-2802 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AEM-2814 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ANG-3070 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 C1 esterase inhibitor (recombinant) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CM-128 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DV-1179 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 F-652 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GSK-2795039 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 GSK-6288B - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ND-07 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 P-2pal18S - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 PZ-235 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 SBP-101 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 SBP-102 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 SP-20201 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ulinastatin - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Pancreatitis - Recent Pipeline Updates 60 Pancreatitis - Dormant Projects 68 Pancreatitis - Discontinued Products 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for Pancreatitis, H1 2016 8 Number of Products under Development for Pancreatitis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Pancreatitis - Pipeline by Angion Biomedica Corp., H1 2016 17 Pancreatitis - Pipeline by Atox Bio Inc., H1 2016 18 Pancreatitis - Pipeline by Bharat Serums And Vaccines Limited, H1 2016 19 Pancreatitis - Pipeline by CalciMedica, Inc., H1 2016 20 Pancreatitis - Pipeline by Dynavax Technologies Corporation, H1 2016 21 Pancreatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 22 Pancreatitis - Pipeline by GlaxoSmithKline Plc, H1 2016 23 Pancreatitis - Pipeline by Pharming Group N.V., H1 2016 24 Assessment by Monotherapy Products, H1 2016 25 Number of Products by Stage and Target, H1 2016 27 Number of Products by Stage and Mechanism of Action, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Pancreatitis Therapeutics - Recent Pipeline Updates, H1 2016 60 Pancreatitis - Dormant Projects, H1 2016 68 Pancreatitis - Discontinued Products, H1 2016 69
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.